The preferably selective 5-HT1B agonist is Xaliproden, which can cause vasoconstriction in the cerebral vessels and have a stabilizing impact on the neurotransmitters, reducing the frequency and severity of migraines [12]. This evidence concerns the gene HTR1B and migraine disorder.